If you're looking for vacancies in our team, please see our main jobs page on the FutureYou website.
Chief Executive Officer
Adam has extensive experience in small and medium companies, with a focus on e-commerce.
He has worked at Abcam, managing teams of analysts and project managers as head of the Business Intelligence and Opportunities department. He was also Operations Director of Hubbub, an online food delivery business in London, and worked as a management consultant for Newton Europe. He has held a non-executive directorship at Bocca di Lupo, Soho’s acclaimed Italian restaurant, since it was founded. He holds an MEng in Engineering, Economics and Management from Oxford University.
Tim is a serial entrepreneur who has successfully built and sold businesses in several different sectors.
He was previously a non-executive director at Abcam plc, prior to which he was Chief Executive and then Chairman of Ransom plc, which he built into one of the UK’s largest natural healthcare groups. He is an active angel investor and a member of the Cambridge Angels investor group. Appointed as interim CEO of Cambridge Nutraceuticals as part of the December 2012 financing round, he took the role of Executive Chairman in April 2015 on the appointment of Adam Cleevely as CEO. He is also a trustee of the Whitley Fund for Nature. Tim is an Economics Exhibitioner and graduate of Cambridge University.
Chief Financial Officer
A Chartered Accountant, Laura joined the Board of Cambridge Nutraceuticals in 2018 to play a key role in shaping the strategic future of the company and promoting its long term success. After an early career at Deloitte, Laura held Group Financial Controller roles at Xaar plc, a listed manufacturer of industrial inkjet printheads, and then Abcam plc, a global leader in the supply of protein-research tools, going on to lead the Investor Relations discipline.
She most recently held the role of CFO at Congenica, where she was recognised as one of the top 50 female leaders in the UK life science sector for two years running. She has a passion for supporting businesses through periods of rapid growth and innovation, and streamlining systems and processes to maintain operational efficiency.
Danielle Miller, PhD
Chief Operating Officer
Danielle spent 16 years at Abcam plc, most recently as Operations Director with global responsibilities. She championed early investment in automated storage solutions across logistics hubs in the UK, US, China & Japan, leading to the company’s stellar reputation for fast, reliable delivery of products.
Prior to that she built Abcam’s global, multilingual customer service and scientific support functions and helped establish the company’s first two overseas offices. Most recently, she led on negotiating lease terms and agreeing the design of a bespoke 100k sq ft facility to house Abcam’s global HQ, which is now under construction at the Cambridge Biomedical Campus.
Prior to joining Abcam Danielle worked as a strategic management consultant. She holds a PhD in plant virology and a degree in Natural Sciences, both from the University of Cambridge.
Chief Technology Officer
The former Head of Software Development at Abcam, Chris held a variety of software development and architecture roles at the company, and more recently at UL EHS Sustainability. Chris has extensive experience of software engineering, architecture, DevOps, development life cycles, project management, line management and business analysis.
He has worked with large IT teams and understands first-hand the challenges of scaling up from a small to a large organisation.
Head of Business Development
Chris has been involved with Cambridge Nutraceuticals from its early days. He has extensive experience in over-the-counter and generic pharmaceutical product management, as well as three years in product marketing management with LloydsPharmacy.
Miriam Ferrer, PhD
Head of Product Development
Miriam was Product Manager at Abcam plc for six years. She was responsible for the commercial marketing strategy for the Cellular Assays range, which included identification and addition of products of interest for researchers, as well as directing tactical marketing activities. Prior to that, she worked for three years in the Business Development team at Abcam, where she was involved in sourcing manufacturing partners.
Before joining a commercial enterprise she spent three years doing post-doctoral research at the MRC Laboratory of Molecular Biology in Cambridge. She holds a PhD in cancer biology from Free University Amsterdam.
Tim studied Mathematics at Cambridge University. He has extensive experience of both academic and practical statistical and data analysis. Recently he worked at a large Cambridge biotech business to optimize stocking algorithms, identify customer needs and drive higher product quality.
Tudor joined Cambridge Nutraceuticals in August 2016. He has extensive experience in web application development and has worked on web systems in diverse sectors, including the US health insurance industry and fashion e-commerce.
Jim brings substantial board-level experience in public and private companies, particularly in high growth journeys from start-up through to IPO and international operations. Most notably, he was COO of Abcam from 2003 to 2016, credited with scaling the company’s industry-leading IT and e-commerce developments.
Jim was formerly Head of IT and Software at Analysis Ltd, and is a computer science graduate of Cambridge University. He is a Non-Executive Director at Quartix Holdings.
Jeff is a CFO with substantial Board experience in high growth public and private companies in the technology and life science sectors. He was CFO of Abcam from 2007-2016, and oversaw : MitoSciences, Ascent Scientific, Epitomics, Firefly BioWorks and AxioMx.
He is also a Non-Executive Director of Treatt.
Mr Peter Kirkpatrick
Peter Kirkpatrick is key medical advisor at Cambridge Nutraceuticals. He is a senior specialist neurosurgeon at Addenbrooke’s Hospital, a world-class centre of medical expertise.
The hospital is affiliated to the University of Cambridge and makes up part of the research-based Cambridge Biomedical Campus.
Peter is a leading expert on strokes and arterial and vascular disease affecting the brain, and has published more than 200 studies. He is also president of the Cambridgeshire branch of Headway, the brain injury charity, and has been a major fundraiser for their work. His input into the analysis of research on ATERONON HEART+, and advice on future research priorities, is invaluable to the development of the business.
Professor Michael Heinrich
Michael Heinrich is a Professor of Ethnopharmacology and Medicinal Plant Research (Pharmacognosy) at University College London School of Pharmacy, and was until recently the head of the research cluster there. He currently serves as the joint chair of UCL’s Research Ethics Committee.
As the author of more than 300 published peer-reviewed papers, Michael is widely cited and recognised as an expert in the field of medicinal plant research. His key areas of interest include the prevention and early stage management of diabetes (metabolic syndrome) and cancer chemoprevention based on the use of traditional medicines, as well as best practice in the supply of herbal medical products/botanicals.